A Prospective Randomized, Open-label Phase 2 Study of Immune Checkpoint Inhibition, Nivolumab With or Without Ipilimumab in Combination With Radiation Therapy in Pretreated Patients With Metastatic Pancreatic Cancer.
Phase of Trial: Phase II
Latest Information Update: 14 Mar 2017
At a glance
- Drugs Nivolumab (Primary) ; Ipilimumab
- Indications Pancreatic cancer
- Focus Therapeutic Use
- Acronyms CheckPAC
- 02 Dec 2016 Status changed from not yet recruiting to recruiting.
- 10 Nov 2016 Planned End Date changed from 1 Aug 2019 to 1 Nov 2019.
- 10 Nov 2016 Planned primary completion date changed from 1 Aug 2018 to 1 Nov 2018.